2007
DOI: 10.1089/cap.2007.1723
|View full text |Cite
|
Sign up to set email alerts
|

Asperger's Disorder and Co-Morbid Bipolar Disorder: Diagnostic and Treatment Challenges

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
6
0

Year Published

2009
2009
2020
2020

Publication Types

Select...
4
4

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(6 citation statements)
references
References 24 publications
0
6
0
Order By: Relevance
“…Twenty-four papers were deemed to potentially meet the review inclusion criteria. Of these, 18 papers were excluded, either as these constituted reviews (Carpenter, 2007;Schneier, Blanco, Antia & Liebowitz, 2002), or as there were no paranoia data about individuals with ASD (Skokauskas & Gallagher, 2012), or because the studies did not report outcome measures pertaining to paranoia in individuals with ASD (Bara, Ciaramidaro, Walter & Adenzato, 2011;Collacott, Cooper & McGrother, 1992;Couture, Penn, Losh, Adolphs, Hurley & Piven, 2009;Gutkovich, Carlson & Carlson, 2007;Hallerbäck, Lugnegård & Gillberg, 2012;Konstantareas & Hewitt, 2001;Murphy, 2006;Pary, 1993;Pilowsky, Yirmiya, Arbelle & Mozes, 2000;Prado de Oliveira, 1999;Shastri, Alla & Sabaratnam, 2006;Siegel et al, 2014;Travé Rodriguez, Barreiro Marin, Galvez Borrero, del Olmo Romero-Nieva & Diaz Alvarez, 1994;Yan et al, 2000), or as paranoia outcome data about individuals with ASD were subsumed and subsequently analysed in a more recent paper (Pinkham, Hopfinger, Pelphrey, Piven & Penn, 2008). One further study was identified which was published during manuscript preparation, and sub-group data were obtained MT personal communication, July 2015).…”
Section: Search Results and Data Extractionmentioning
confidence: 99%
“…Twenty-four papers were deemed to potentially meet the review inclusion criteria. Of these, 18 papers were excluded, either as these constituted reviews (Carpenter, 2007;Schneier, Blanco, Antia & Liebowitz, 2002), or as there were no paranoia data about individuals with ASD (Skokauskas & Gallagher, 2012), or because the studies did not report outcome measures pertaining to paranoia in individuals with ASD (Bara, Ciaramidaro, Walter & Adenzato, 2011;Collacott, Cooper & McGrother, 1992;Couture, Penn, Losh, Adolphs, Hurley & Piven, 2009;Gutkovich, Carlson & Carlson, 2007;Hallerbäck, Lugnegård & Gillberg, 2012;Konstantareas & Hewitt, 2001;Murphy, 2006;Pary, 1993;Pilowsky, Yirmiya, Arbelle & Mozes, 2000;Prado de Oliveira, 1999;Shastri, Alla & Sabaratnam, 2006;Siegel et al, 2014;Travé Rodriguez, Barreiro Marin, Galvez Borrero, del Olmo Romero-Nieva & Diaz Alvarez, 1994;Yan et al, 2000), or as paranoia outcome data about individuals with ASD were subsumed and subsequently analysed in a more recent paper (Pinkham, Hopfinger, Pelphrey, Piven & Penn, 2008). One further study was identified which was published during manuscript preparation, and sub-group data were obtained MT personal communication, July 2015).…”
Section: Search Results and Data Extractionmentioning
confidence: 99%
“…Comorbid conditions such as schizophrenia, bipolar disorder and attention-deficit hyperactivity disorder have been reported in Asperger's Syndrome 9,10). Furthermore, symptoms such as obsession may predict the prodromal phases of other psychiatric disorders.…”
Section: Discussionmentioning
confidence: 99%
“…If these behaviors occur during episodes that represent a change from the person's usual function, both PDD and bipolar disorder are diagnosed (e.g., Gutkovich, Carlson, Carlson, Coffey, & Wieland, 2007;Wozniak et al, 1997).…”
Section: Treatment Of Bipolar Disorder In Developmentally Disabled Youthmentioning
confidence: 99%
“…Two case reports (Frazier & Jackson, 2008;Gutkovich, Carlson, Carlson, Coffey, & Wieland, 2007) describe risperidone's efficacy in autism spectrum youth with bipolar disorder. On the other hand, and very relevant for treatment of behaviors characteristic of mania, risperidone has been studied extensively in children and adolescents with irritable and agitated behavior in autism (e.g., and has recently received FDA approval for treatment of irritability and self-injurious behavior in autism.…”
Section: Atypical Antipsychoticsmentioning
confidence: 99%